UK-based — my mhealth NHS-approved digital therapeutics company with three European collaborators has bagged €2.5 million (nearly £2.2 million) Eurostars Grant for the development of CUOREMA, their innovative programme.
Supports cardiac rehabilitation in Europe
Cardiovascular disease is a leading cause of death globally with an estimated 17.9 million deaths each year. Many CVD-related deaths can be prevented by targeting risk factors such as blood pressure, smoking, diet, and exercise. Immersive cardiac rehabilitation app, myHeart uses behavioural feedback and gamification features to improve patient well-being and support cardiac rehabilitation in Europe.
Intelligent cardiac rehabilitation support system
The Bournemouth-based startup’s CUOREMA project will focus on developing a new, patient-centered and intelligent cardiac rehabilitation support system. The scalable, customisable, and flexible technology will provide a new systematic method of social and biological feedback from wearable devices. The app will include inbuilt behaviour change support systems with mixed reality and immersive technology to improve medical adherence and clinical outcomes.
Dr. Simon Bourne, Chief Executive Officer of my mhealth said: “We are thrilled to be partnering with such talented and diverse teams on this innovative and important project over the next few years. Each organisation brings a very unique perspective to the table, allowing for a thoughtful and comprehensive approach to tackling heart health. I am extremely passionate about digital health and this has the potential to change many lives for the better, helping us transform cardiac rehabilitation for patients across Europe.”
UK’s first NHS-approved digital platform
Founded by two NHS medical consultants – Simon Bourne and Tom Wilkinson in 2021, my mhealth works with the mission to change healthcare forever. The company empowers patients and clinical teams to manage long-term conditions using digital therapeutics. These are delivered remotely at a fraction of the traditional cost to patients with asthma, COPD, COVID-19, diabetes and heart diseases.
The company has developed the UK’s first NHS-approved digital platform. my mhealth delivered over 275,000 rehabilitation and education sessions during 2020 to patients with respiratory and cardiac conditions. It is a clinical and technological expert in digital healthcare applications for long-term conditions and its primary focus is COPD. As it follows strict guidelines, the app will be compatible for use across the European Union. Upon development, the app content will be available in five languages including French, Italian, Portuguese, German, and Spanish.
Eurostars is a European joint programme, co-funded from the national budgets of 36 EUREKA countries and by the European Union through Horizon 2020. Also, Innovate UK will sponsor my mhealth to develop part of its myHeart app to support cardiac rehabilitation in Europe.